Sponsor

Apices Soluciones S.L.

Clinical research sponsor

Published trials9

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

9 shown

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.NCT07333066 · collaborator · 2026-06-05

RECRUITING

Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer DiagnosisNCT07465848 · collaborator · 2025-10-08

RECRUITING

Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).NCT07406789 · collaborator · 2026-02-11

NOT_YET_RECRUITING

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainNCT06764186 · collaborator · 2025-01-07

ACTIVE_NOT_RECRUITING

Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.NCT04483505 · collaborator · 2020-11-25

COMPLETED

Palbociclib and Binimetinib in Advanced Triple Negative Breast CancerNCT04494958 · collaborator · 2020-11-18

COMPLETED

Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)NCT03434158 · collaborator · 2018-02-06

COMPLETED

Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate CancerNCT02288936 · collaborator · 2015-02-05

COMPLETED

Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.NCT02036060 · collaborator · 2014-02-07

COMPLETED

Sponsor roles

collaborator9

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.